Novartis

Novartis
Basel, North West Switzerland
Web: Novartis external link
Location: Basel
Related to:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.
#display_name

Medicine Sep 22
CMLPath to Care(TM) collaboration replaces Glivec International Patient Access Program (GIPAP) with a new, independent, patient-centered access model -   GIPAP was introduced 15 years ago and has provided approximately 75,000 patients access to free, cancer treatment -   The Max Foundation to lead program for patients and oversee supply chain ma
Medicine Sep 20

Novartis drug Rydapt (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM) Significant overall surv

Medicine Sep 14

51-week clinical study confirms that Sandoz proposed biosimilar adalimumab matches reference medicine Humira * safety and efficacy profile Sandoz proposed biosimilar adalimumab is currently under r

Medicine Sep 12

Rituximab is indicated to treat blood cancers and immunological diseases such as rheumatoid arthritis Sandoz believes the comprehensive data package submitted to the FDA for review confirms that ou

Medicine Sep 16

OPTIMA Phase IIIb data re-confirm that almost two thirds of patients treated with Xolair 300 mg for 6 months are well-controlled -   Should a treatment pause be necessary, data showed almost 90% of

Medicine Sep 13

Cosentyx (secukinumab) is the first and only fully human IL-17A   inhibitor to show sustained skin clearance rates at 5 years in phase III in psoriasis -   Landmark data show that PASI 90 and PASI

Medicine Sep 11

Novartis Phase III study demonstrates adjuvant Tafinlar + Mekinist reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma The three-year relaps




 
 
Logo Careerjet